Orthofix Medical (NASDAQ:OFIX) Announces Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Key Points

• Orthofix reported Q1 EPS of -$0.52, beating estimates by $0.16, with revenue of about $196.7M, and reaffirmed full‑year guidance of $850–860M in net sales and $95–98M adjusted EBITDA with positive free cash flow expected.
• Management said distributor transitions are largely complete and commercial execution is driving growth—top 30 U.S. distributors grew net sales 27% YoY—and the company is pushing adoption of the 7D FLASH ecosystem with a full‑market launch of Virada slated for H2 2026, though biologics remains a near‑term risk.
• Shares fell about 2% to $12.19 amid mixed analyst ratings (consensus "Hold", $17.25 target); financials show improving margins (pro forma gross margin 70.7%, Q1 adj. EBITDA $9.7M) and a cash balance of $120.9M, while major shareholder Engine Capital added to its stake.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) issued its quarterly earnings results on Tuesday. The medical device company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.16, FiscalAI reports. Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The firm had revenue of $196.71 million during the quarter, compared to analyst estimates of $196.40 million.

Here are the key takeaways from Orthofix Medical's conference call:

• Company reported a solid start to 2026 with total net sales of $196.4M (up 3% pro forma) and reaffirmed full‑year guidance of $850–860M in net sales and $95–98M adjusted EBITDA, with positive free cash flow expected.
• Management simplified spine leadership and says distributor transitions are largely complete, positioning the business to accelerate as it pushes adoption of the 7D FLASH ecosystem and the full‑market launch of Virada in H2 2026.
• Execution with prioritized partners is driving results — the top 30 U.S. distributors grew net sales 27% YoY (24% on a trailing 12‑month basis), which management highlights as validation of its distributor strategy.
• Biologics remain a weak spot despite sequential improvement; the business was realigned under limb reconstruction leadership and management expects a return to market growth, but it represents a near‑term execution risk.
• Financial and margin trends showed improvement, with pro forma non‑GAAP adjusted gross margin at 70.7% (up 40 bps), Q1 adjusted EBITDA of $9.7M, and a cash balance of $120.9M.

Orthofix Medical Trading Down 2.0%

Shares of Orthofix Medical stock traded down $0.25 during trading hours on Wednesday, hitting $12.19. The company's stock had a trading volume of 502,781 shares, compared to its average volume of 266,247. Orthofix Medical has a 1-year low of $10.24 and a 1-year high of $16.99. The business has a fifty day moving average of $12.24 and a 200 day moving average of $13.93. The company has a market capitalization of $489.31 million, a PE ratio of -5.21 and a beta of 0.79. The company has a quick ratio of 1.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.39.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on OFIX shares. Canaccord Genuity Group dropped their price target on shares of Orthofix Medical from $24.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Barrington Research reissued an "outperform" rating and issued a $17.00 price objective on shares of Orthofix Medical in a research report on Friday, April 10th. Wall Street Zen lowered shares of Orthofix Medical from a "buy" rating to a "hold" rating in a research report on Saturday. Stifel Nicolaus dropped their price objective on shares of Orthofix Medical from $22.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, March 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Orthofix Medical in a research report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Orthofix Medical currently has a consensus rating of "Hold" and a consensus target price of $17.25.

Insider Transactions at Orthofix Medical

In other news, major shareholder Engine Capital Management, Lp purchased 13,061 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average cost of $12.96 per share, with a total value of $169,270.56. Following the acquisition, the insider owned 3,673,092 shares in the company, valued at approximately $47,603,272.32. This trade represents a 0.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jorge Andres Cedron sold 3,743 shares of the firm's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $12.82, for a total transaction of $47,985.26. Following the sale, the insider directly owned 59,006 shares of the company's stock, valued at approximately $756,456.92. The trade was a 5.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Orthofix Medical

Large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its holdings in Orthofix Medical by 12.9% during the 3rd quarter. Franklin Resources Inc. now owns 24,595 shares of the medical device company's stock valued at $360,000 after purchasing an additional 2,816 shares in the last quarter. AQR Capital Management LLC grew its holdings in Orthofix Medical by 67.7% during the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company's stock valued at $333,000 after purchasing an additional 8,241 shares in the last quarter. Walleye Capital LLC acquired a new stake in Orthofix Medical during the 4th quarter valued at $275,000. Oxford Asset Management LLP acquired a new stake in Orthofix Medical during the 2nd quarter valued at $250,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Orthofix Medical during the 4th quarter valued at $238,000. 89.76% of the stock is owned by institutional investors and hedge funds.

Orthofix Medical Company Profile

Orthofix Medical Inc NASDAQ: OFIX is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.